Cannabidiol (CBD), a component of Cannabis sativa L, has in recent years attracted increasing interest as a treatment for a range of neuropsychiatric disorders. The purpose of the current research is to determine the potential of CBD as a treatment for anxiety-related disorders by evaluating data from pre-clinical, human experimental, clinical and epidemiological studies.
This study found that existing preclinical evidence strongly supports CBD as a treatment for generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder and post-traumatic stress disorder when administered acutely. However, few studies have investigated chronic CBD dosing.
Similarly, evidence from human studies supports the anxiolytic role of CBD, but is currently limited to acute dosing.
Overall, current evidence suggests that CBD has significant potential as a treatment for multiple anxiety disorders, with a need for further study of its chronic and therapeutic effects in humans.
Source: Pubmed, National Library of Medicine, Neurotherapeutics